CEL-SCI Corporation is a company focused on the research and development of immunotherapy for cancer and infectious diseases. Its lead investigational immunotherapy, Multikine is undergoing phase III clinical trials for the treatment of head and neck cancer. The company also develops product candidates for the treatment of rheumatoid arthritis and COVID-19 coronavirus.